Filing Flows › Health Care › Gyre Therapeutics (GYRE)
Gyre Therapeutics (GYRE) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Gyre Therapeutics (GYRE) Q3 2026 earnings results →
Q3 2026 Revenue up 1% year over year to $32.9M · 8¢ of every $1 of revenue lost · operating margin -4.6%
Gyre Therapeutics made $32.9M in Q3 2026 (+0.7% Y/Y): Gyre Pharmaceuticals $32.4M, Gyre $508K. Operating margin -4.6%, net loss $2.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $32.9M in Q3 2026, up 1% year over year and up 13% from the previous quarter. Gyre Pharmaceuticals was the largest line at 98% of revenue. Gyre Pharmaceuticals added $1.9M year over year (up 6%), 776% of the total change. Gyre declined 76%.
Operating costs exceeded revenue by $1.5M, an operating margin of -4.6%. The fastest-growing cost line was Other operating costs (+78%). The quarter ended with a net loss of $2.5M, narrower than the previous quarter's $23.0M loss.
Operating cash flow was −$4.0M. Non-cash charges added back $467K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $3.7M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$5.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $32.9M | +0.7% | -4.6% | −$2.5M | −$4.0M |
| Q2 2026 | 10-Q | Aug 7, 2026 | $29.1M | -2% | -49.3% | −$23.0M | −$16.7M |
| Q1 2026 | 10-Q | May 8, 2026 | $22.5M | +2% | -41.5% | −$9.9M | $3.2M |
| Q4 2025 | 10-K | Mar 13, 2026 | $37.2M | +33% | 0.3% | −$1.4M | −$5.6M |
| Q3 2025 | 10-Q | Nov 7, 2025 | $30.6M | +20% | 22.7% | $5.9M | $4.7M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $26.8M | +6% | 8.1% | $1.6M | $2.1M |
| Q1 2025 | 10-Q | May 9, 2025 | $22.1M | -19% | 10.3% | $3.7M | −$129K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Sinopharm Group Company Limited — 52% of its revenue · Stated in 10-K (XBRL) · source
- China Resources Pharmaceutical Group Limited — 13% of its revenue · Stated in 10-K (XBRL) · source
- Shanghai Pharmaceuticals Holding Company Limited — 12% of its revenue · Stated in 10-K (XBRL) · source
About Gyre Therapeutics
In this section, unless otherwise specified, references to “we,” “our,” “us” and “our company” refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (“Gyre Pharmaceuticals”). We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S. operations headquartered in San Diego, California.
In its own words, from its 10-K, filed Mar 13, 2026.
Gyre Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +0.7% against the peers' median +7%. Operating margin: -4.6% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GYRE Gyre Therapeutics | Q3 2026 | $32.9M | +0.7% | -4.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Gyre Therapeutics 10-Q on SEC EDGAR · CIK 1124105 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns GYRE and who is buying
More on GYRE
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Gyre Therapeutics guidance history: guided vs reported
- Gyre Therapeutics gross margin by quarter
- Gyre Therapeutics operating margin by quarter
- Gyre Therapeutics net income by quarter
- Gyre Therapeutics free cash flow by quarter
- Gyre Therapeutics R&D spending by quarter
- Gyre Therapeutics capital expenditures by quarter